Reference health
Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model
36/36 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 36 checked references that resolve
resolves10.1091/mbc.e10-03-0240
Forced Homo- and Heterodimerization of All gp130-Type Receptor Complexes Leads to Constitutive Ligand-independent Signaling and Cytokine-independent Growth
resolves10.1002/btpr.746
Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in <i>E. coli</i> with stop codon optimization
resolves10.1155/2017/1975902
Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use
resolves10.1371/journal.ppat.1006902
Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
resolves10.1074/jbc.M113.461756
Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer*
resolves10.4049/jimmunol.177.9.6072
Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo
resolves10.1016/j.cyto.2018.01.011
Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
resolves10.1182/blood-2011-10-384362
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum
resolves10.1074/jbc.M115.695304
Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity
resolves10.1074/jbc.M508624200
Soluble Interleukin-15 Receptor α (IL-15Rα)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rβ/γ
resolves10.1016/j.cyto.2011.09.028
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
resolves10.1038/s41598-018-25987-4
Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy
resolves10.1074/jbc.M706150200
Crystal Structure of the Interleukin-15·Interleukin-15 Receptor α Complex
resolves10.1007/s10719-015-9627-1
Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation
resolves10.1158/1535-7163.MCT-09-0275
High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer
resolves10.1016/j.cyto.2017.12.003
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
resolves10.1016/j.cell.2018.09.035
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
resolves10.1080/21645515.2016.1175694
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
resolves10.1158/1078-0432.CCR-10-1966
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
resolves10.4049/jimmunol.1600019
IL-15 <i>Trans</i>-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
resolves10.1007/s00253-016-7973-y
Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein
resolves10.1007/s00253-018-9021-6
Rapid development of stable transgene CHO cell lines by CRISPR/Cas9-mediated site-specific integration into C12orf35
resolves10.1016/j.jim.2009.07.010
MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of Interleukin-15: Assay qualification, standardization and statistical analysis
resolves10.1007/s00253-016-7848-2
A novel self-cleavable tag Zbasic–∆I-CM and its application in the soluble expression of recombinant human interleukin-15 in Escherichia coli
resolves10.1007/s11095-011-0597-0
Characterization of Recombinant Human IL-15 Deamidation and Its Practical Elimination through Substitution of Asparagine 77
resolves10.4049/jimmunol.180.4.2099
Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
resolves10.1038/gt.2014.84
Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells
resolves10.1016/j.pep.2011.12.009
Expression and purification of recombinant human Mig in Escherichia coli and its comparison with murine Mig
resolves10.1038/s41598-017-08641-3
Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system
resolves10.1158/1078-0432.CCR-16-1808
Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion
resolves10.1002/ijc.29686
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
resolves10.1210/en.2015-1746
Free IL-15 Is More Abundant Than IL-15 Complexed With Soluble IL-15 Receptor-α in Murine Serum: Implications for the Mechanism of IL-15 Secretion
resolves10.1007/s00253-017-8265-x
Purification of inclusion bodies using PEG precipitation under denaturing conditions to produce recombinant therapeutic proteins from Escherichia coli
resolves10.1371/journal.pone.0109801
Myxoma Virus Expressing a Fusion Protein of Interleukin-15 (IL15) and IL15 Receptor Alpha Has Enhanced Antitumor Activity
resolves10.1016/j.ymthe.2018.07.013
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
The 3 references without a DOI — listed, not checked
no DOI — not checkedCytokine-mediated regulation of CD8 T-Cell responses during acute and chronic viral infection
no DOI — not checkedNivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag24-/-IL2Rynull immunodeficient mice
no DOI — not checkedALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial, The Lancet
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.biopha.2019.108677"><img src="https://citestamp.com/citestamped/10.1016/j.biopha.2019.108677/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.biopha.2019.108677)